Quantcast

Latest Thrombocytopenia Stories

2009-03-26 16:27:00

WASHINGTON, March 26 /PRNewswire-USNewswire/ -- Two Miami-area residents pleaded guilty today in connection with a $10 million Medicare fraud scheme involving HIV infusion clinics, Acting Assistant Attorney General Rita M. Glavin of the Criminal Division and U.S. Attorney R. Alexander Acosta of the Southern District of Florida announced. Dr. Carmen Del Cueto, 65, and Alexis Dagnesses, 44, each pleaded guilty to one count of conspiracy to commit health care fraud before U.S. District Judge...

2009-02-06 16:45:00

First and Only Approved Platelet Producer in Europe Represents New Treatment Approach for Serious Chronic Autoimmune Disorder ZUG, Switzerland, Feb. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that the European Commission (EC) has granted marketing authorisation for Nplate(R) (romiplostim) for the treatment of splenectomised adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g. corticosteroids,...

2009-01-20 07:30:00

SHENYANG, China, Jan. 20 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it filed on December 30, 2008 with the Chinese State Food and Drug Administration (SFDA) for approval of a TPIAO label extension for the treatment of idiopathic thrombocytopenic purpura (ITP) in China. If the extension is approved, 3SBio expects...

2008-12-08 13:00:00

SAN FRANCISCO, Dec. 8 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today released updated results from the ongoing, open-label extension study of the long-term safety and efficacy of Nplate(TM) (romiplostim) in adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a chronic and serious autoimmune disorder characterized by lower than expected platelet counts in the blood, sometimes leading to serious bleeding events. The results were presented today as an...

2008-12-08 12:30:00

CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today reported positive results from AEGIS, an open-label registration study examining Soliris(R) (eculizumab) treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-specified primary efficacy endpoint of change in hemolysis was achieved with an 86 percent reduction (P<0.001). Key secondary endpoints including fatigue (P<0.001) and transfusions/anemia...

2008-12-06 11:00:00

SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood, will be presented in a press conference on Saturday, December 6, at 8:00 a.m., during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. The studies featured in the press conference will...

2008-12-06 10:00:00

PHILADELPHIA, Dec. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced positive safety and efficacy results from RAISE (RAndomized placebo- controlled ITP Study with Eltrombopag), a Phase III study of PROMACTA(R) (eltrombopag) in adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who had received one or more prior ITP therapies. Patients receiving PROMACTA were eight times more likely than those on placebo to maintain platelet counts between 50,000 to...

2008-10-23 09:00:38

Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that it had a very fruitful and productive scientific meeting with the FDA to discuss the safety and development of Oxycyte(R) in Traumatic Brain Injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier. The company has subsequently decided to expand its research plan to include a sequential dose escalation safety and efficacy study of up to 40 patients. Due to the slight redesign of the protocol and...

2008-10-15 12:00:33

Under a new program introduced by Talecris Biotherapeutics, patients who regularly use Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) may be able to receive continuing treatment in the event of a lapse in private insurance coverage. Gamunex is an immunoglobulin intravenous (IGIV) therapy that contains antibodies purified from the donated blood plasma of thousands of people. Gamunex is indicated as replacement therapy of primary humoral...

2008-10-11 03:00:05

By Naina, Harris V K Harris, Samar; Pham, Angie; Wang, Jun To the Editor.-In the review article on Bernard-Soulier syndrome (BSS), Pham and Wang1 reported the May-Hegglin anomaly as the most common inherited giant platelet disorder. We disagree with the authors regarding that statement. To date, only 200 families, to our knowledge, have been studied for MYH9-related disorders. Harris platelet syndrome (HPS), previously called asymptomatic constitutional macrothrombocytopenia, is an...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related